Skip to main content
SpringerLink
Log in

Use of thrombolytics: benefits justify additional costs

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gillis JC, Goa KL. Streptokinase: a pharmacoeconomic appraisal of its use in the management of acute myocardial infarction. Pharmacoeconomics 1996 Sep; 10: 281–310

    Article  PubMed  CAS  Google Scholar 

  2. Barthel W, Haustein K-O. Cost-benefit analysis — a prerequisite of a rational pharmacotherapy in cardiovascular diseases. Int J Clin Pharmacol Ther 1996 Jul; 34: 277–81

    PubMed  CAS  Google Scholar 

  3. Barradell LB, Goa KL. Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction. Pharmacoeconomics 1995 Nov; 8: 428–59

    Article  PubMed  CAS  Google Scholar 

  4. Woo KS, White HD. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents. Pharmacoeconomics 1993 Mar; 3: 192–204

    Article  PubMed  CAS  Google Scholar 

  5. Topol E, Califf R, Van de Werf F. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993 Sep 2; 329: 673–82

    Article  Google Scholar 

  6. Goldman L, Garber AM, Grover SA, et al. Task force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996 Apr; 27: 1020–30

    Article  PubMed  CAS  Google Scholar 

  7. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995 May 25; 332: 1418–24

    Article  PubMed  CAS  Google Scholar 

  8. Ramanathan K, Ellis CJ, White HD. Thrombolytic therapy in the elderly: pharmacoeconomic considerations. Drugs Aging 1996 Apr; 8: 237–44

    Article  PubMed  CAS  Google Scholar 

  9. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992 Jul 2; 327: 7–13

    Article  PubMed  CAS  Google Scholar 

  10. Using drug utilisation review to assess the appropriateness of thrombolytic therapy. Drug Ther Perspect 1995 May 1; 5 (8): 14-6

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Use of thrombolytics: benefits justify additional costs. Drugs Ther. Perspect 8, 14–16 (1996). https://doi.org/10.2165/00042310-199608110-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199608110-00005

Search

Navigation